PHLDA2

Across TCGA pan-cancer cohorts, PHLDA2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of PHLDA2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where PHLDA2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PHLDA2 is over-expressed in tumor, although a few such as KICH and KIRP show the opposite, repressed pattern.

COAD, THCA, and LUAD are the cancer types where PHLDA2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PHLDA2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+1.865	<.001	11	view →
THCA	Male	III,IV	+2.300	<.001	10	view →
LUAD	Female	III,IV	+3.218	<.001	9	view →
STAD	All	All	+2.285	<.001	9	view →
KICH	Female	II,III,IV	−3.288	<.001	8	view →
LIHC	Male	III,IV	+2.567	<.001	7	view →
LUSC	All	All	+1.041	<.001	7	view →
UCEC	All	II,III,IV	+2.373	<.001	6	view →
HNSC	Male	All	+1.275	<.001	6	view →
BRCA	All	All	+0.806	<.001	6	view →
READ	All	III,IV	+1.935	.027	4	view →
CHOL	Male	All	+3.748	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

PHLDA2–COAD

Open the COAD breakdown →